Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting

NCT06581328 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06581328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06581328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Recruiting
Start date
March 27, 2025
Completion date
June 1, 2028
Enrollment
200 (estimated)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ulcerative colitis